Compare OPAD & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAD | NXTC |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | 140 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.3M | 39.1M |
| IPO Year | N/A | 2019 |
| Metric | OPAD | NXTC |
|---|---|---|
| Price | $0.64 | $9.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $1.83 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 632.3K | 45.6K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.42 |
| 52 Week High | $6.35 | $15.74 |
| Indicator | OPAD | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 37.33 | 45.35 |
| Support Level | $0.57 | $8.45 |
| Resistance Level | $0.90 | $10.81 |
| Average True Range (ATR) | 0.06 | 0.74 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 12.88 | 45.80 |
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.